- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02224365
The Effects of Apple Consumption on Cardiovascular Health in Prediabetics and Type 2 Diabetics
December 6, 2016 updated by: Bahram Arjmandi, Florida State University
Regular Apple Consumption Improves Cardiovascular Risk Factors and Glycemic Control in Overweight and Obese Prediabetics and Type 2 Diabetics
The hypothesis of this study is that the daily consumption of 75 g dried apple powder for twelve weeks will improve arterial stiffness and blood pressure by improving endothelial-mediated vasodilation and vascular sympathetic activity and favorably altering biochemical markers associated with cardiovascular risk and glycemic control compared to a macronutrient-matched control powder.
50 men and women between the ages of 45 and 65 with prediabetes or type 2 diabetes who are overweight or obese will be included in the study.
After a two-week run-in phase, eligible men and women will be randomly assigned to one of two treatment groups: 1) 75 g dried apple powder; or 2) 75 g placebo powder daily for twelve weeks.
After an initial telephone screening, all participants will be requested to report to the study site for their first visit.
On the first visit (screening), participants will be provided with verbal and written explanation of the project.
They will then be asked to sign an informed consent form, followed by measuring fasting glucose levels and a medical history questionnaire to confirm prediabetes or type 2 diabetes.
Baseline assessments will be performed for medical history, medication use, dietary intake, and physical activity.
Qualified participants will be scheduled for their second visit two weeks later (actual baseline data collection) and randomly assigned to their treatment group.
On the second (baseline) visit between the hours of 6:00-11:00 A.M., blood pressure and vascular function will be measured followed by blood draw and urine collection.
Anthropometrics will be measured.
Participants will be provided with their assigned treatment and will receive standard instructions on how to fill out daily diaries for their treatment, and for food and physical activity records.
Blood pressure, vascular function, blood draw, urine collection, and anthropometric, body composition, diet, and physical activity assessments will be repeated at 6- (third visit), and 12-week (final visit) intervals.
All cardiovascular measurements will be performed between 6:00 to 11:00 A.M., in a quiet temperature-controlled room in the supine position after an overnight fast and 12 hours after the abstinence of caffeine and/or 24 hours after the last bout of moderate to heavy physical activity.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Tallahassee, Florida, United States, 32306
- Department of Nutrition, Food and Exercise Sciences, Center for Advancing Exercise and Nutrition Research on Aging, Florida State University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women (1 to 10 years postmenopausal)
- Aged 45-65 years
- Prediabetes or Type 2 Diabetes (Hemoglobin A1c ≥ 5.7%)
- Overweight or obese (body mass index between 25 and 40 kg/m2)
Exclusion Criteria:
- Diagnosed cardiovascular disease
- Uncontrolled hypertension (≥ 160/100 mmHg)
- Other active chronic diseases such as cancer, asthma, glaucoma, thyroid, kidney, liver and pancreatic disease
- Participating in a weight loss program
- Heavy smokers (> 20 cigarettes per day)
- Heavy drinkers (> 12 alcoholic drinks per week)
- Consumption of more than two apples per week
- Body mass index less than 25 or greater than 40 kg/m2)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Apple
12 weeks of 75 g dried apple powder taken in 480 ml per day.
|
12 weeks of 75 g dried apple powder taken in 480 ml per day.
|
Placebo Comparator: Placebo
12 weeks of 75 g apple-flavored placebo powder taken in 480 ml per day.
|
12 weeks of 75 g apple-flavored placebo powder taken in 480 ml per day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood Pressure
Time Frame: 12 weeks
|
By measuring brachial and aortic blood pressure at rest and during physiological stress (handgrip exercise and post-exercise muscle ischemia).
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Inflammation
Time Frame: 12 weeks
|
By measuring markers of inflammation.
|
12 weeks
|
Oxidative Stress
Time Frame: 12 weeks
|
By measuring markers of oxidative stress.
|
12 weeks
|
Insulin Sensitivity
Time Frame: 12 weeks
|
By measuring fasting glucose, insulin, homeostatic model of insulin resistance, and hemoglobin A1C.
|
12 weeks
|
Body Composition
Time Frame: 12 weeks
|
By measuring fat mass and fat-free mass using dual-energy X-ray absorptiometry and anthropometrics.
|
12 weeks
|
Arterial Stiffness
Time Frame: 12 weeks
|
By measuring arterial stiffness and augmentation index at rest and during physiological stress (handgrip exercise and post-exercise muscle ischemia).
|
12 weeks
|
Autonomic Control of Blood Pressure
Time Frame: 12 weeks
|
By measuring blood pressure variability and baroreflex sensitivity at rest and during physiological stress.
|
12 weeks
|
Endothelial-mediated Vasodilation
Time Frame: 12 weeks
|
By measuring flow-mediated dilation in the brachial artery.
|
12 weeks
|
Atherogenic Markers
Time Frame: 12 weeks
|
By measuring adhesion factors, lipid profiles, and atherogenic risk ratios.
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Sarah A. Johnson, PhD, RDN, Department of Food Science and Human Nutrition, Colorado State University
- Principal Investigator: Bahram H. Arjmandi, PhD, RD, Department of Nutrition, Food and Exercise Sciences, Center for Advancing Exercise and Nutrition Research on Aging, Florida State University
- Principal Investigator: Arturo Figueroa, MD, PhD, Department of Nutrition, Food and Exercise Sciences, Florida State University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2014
Primary Completion (Actual)
December 1, 2016
Study Completion (Actual)
December 1, 2016
Study Registration Dates
First Submitted
August 21, 2014
First Submitted That Met QC Criteria
August 21, 2014
First Posted (Estimate)
August 25, 2014
Study Record Updates
Last Update Posted (Estimate)
December 8, 2016
Last Update Submitted That Met QC Criteria
December 6, 2016
Last Verified
December 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RF02435
- 2015.14930 (Other Identifier: FSU IRB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
Nanjing Medical UniversityRecruiting
-
Centre Hospitalier Universitaire de la RéunionRecruitingCardiovascular DiseaseFrance
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular DiseaseUnited States
Clinical Trials on Apple
-
Clinical Nutrition Research Center, Illinois Institute...Completed
-
Maastricht University Medical CenterActive, not recruiting
-
Clinical Research Center Kiel GmbHNofimaCompleted
-
Case Comprehensive Cancer CenterNot yet recruitingGlioblastoma | Seizures | Venous ThromboembolismUnited States
-
Stanford UniversityNot yet recruiting
-
Mayo ClinicEnrolling by invitationAtrial FibrillationUnited States
-
Stanford UniversityMedeloop.aiNot yet recruitingComplex Regional Pain SyndromesUnited States
-
Universidade Federal de Santa CatarinaCompletedOxidative Stress